AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
REGULATORY UPDATE: AABB Introduces New FDA Blood Establishment Registration Toolkit
September 19, 2025
FDA to Host Virtual Town Hall on Gene Therapy Manufacturing
September 11, 2025
REGULATORY UPDATE: FDA Withdraws EUA for COVID-19 Convalescent Plasma
September 10, 2025
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
